AU8260701A - Solution preparations stabilized over long time - Google Patents

Solution preparations stabilized over long time

Info

Publication number
AU8260701A
AU8260701A AU8260701A AU8260701A AU8260701A AU 8260701 A AU8260701 A AU 8260701A AU 8260701 A AU8260701 A AU 8260701A AU 8260701 A AU8260701 A AU 8260701A AU 8260701 A AU8260701 A AU 8260701A
Authority
AU
Australia
Prior art keywords
long time
over long
stabilized over
solution preparations
preparations stabilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU8260701A
Inventor
Yasushi Sato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AU8260701A publication Critical patent/AU8260701A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
AU8260701A 2000-09-01 2001-09-03 Solution preparations stabilized over long time Pending AU8260701A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000266095 2000-09-01
PCT/JP2001/007600 WO2002017957A1 (en) 2000-09-01 2001-09-03 Solution preparations stabilized over long time

Publications (1)

Publication Number Publication Date
AU8260701A true AU8260701A (en) 2002-03-13

Family

ID=18753248

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2001282607A Ceased AU2001282607B2 (en) 2000-09-01 2001-09-03 Solution preparations stabilized over long time
AU8260701A Pending AU8260701A (en) 2000-09-01 2001-09-03 Solution preparations stabilized over long time
AU2006235962A Abandoned AU2006235962A1 (en) 2000-09-01 2006-11-10 Solution formulations having long-term stability

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2001282607A Ceased AU2001282607B2 (en) 2000-09-01 2001-09-03 Solution preparations stabilized over long time

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2006235962A Abandoned AU2006235962A1 (en) 2000-09-01 2006-11-10 Solution formulations having long-term stability

Country Status (9)

Country Link
US (1) US7998929B2 (en)
EP (2) EP1329224A4 (en)
KR (1) KR20030027077A (en)
CN (1) CN1204921C (en)
AU (3) AU2001282607B2 (en)
CA (1) CA2420850A1 (en)
HK (1) HK1057168A1 (en)
NZ (1) NZ524482A (en)
WO (1) WO2002017957A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4147234B2 (en) 2004-09-27 2008-09-10 キヤノン株式会社 Discharge liquid, discharge method, cartridge, and discharge device
AU2003251906B2 (en) * 2002-07-12 2008-12-04 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
JP4489591B2 (en) * 2002-08-27 2010-06-23 中外製薬株式会社 Method for stabilizing protein solution formulations
RU2234945C2 (en) * 2002-10-15 2004-08-27 Вардосанидзе Ирина Викторовна Stabilizing agent for aqueous solution and water-containing raw with spontaneously varying oxidative-reductive properties
KR20120104619A (en) * 2003-08-14 2012-09-21 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Liquid, aqueous pharmaceutical composition of factor vii polypeptides
EP1706150B1 (en) * 2003-12-23 2012-04-25 Pharmacia Corporation Stable growth hormone liquid formulation
CA2565414A1 (en) 2004-05-04 2005-11-24 Novo Nordisk Health Care Ag O-linked glycoforms of polypeptides and method to manufacture them
JP4147235B2 (en) * 2004-09-27 2008-09-10 キヤノン株式会社 Discharge liquid, discharge method, droplet forming method, liquid discharge cartridge, and discharge apparatus
WO2007034509A2 (en) * 2005-09-19 2007-03-29 Zenotech Laboratories Limited Recombinant granulocyte-colony stimulating factor formulation and process
KR100784134B1 (en) 2006-10-09 2007-12-12 주식회사 대웅 Stable liquid compositions for treating mucositis comprising epidermal growth factor
JP5349452B2 (en) * 2007-04-05 2013-11-20 サンド アクチエンゲゼルシャフト Stable aqueous G-CSF formulation
CA2692165A1 (en) * 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
JP5259710B2 (en) 2007-07-10 2013-08-07 メディ‐トックス、インク． Pharmaceutical liquid composition with improved stability of botulinum toxin
AU2008292186B9 (en) * 2007-08-27 2014-07-03 Ratiopharm Gmbh Liquid formulation of G-CSF conjugate
PE20091174A1 (en) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT
SI2542257T1 (en) 2010-03-01 2018-01-31 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
ES2833099T3 (en) 2015-02-11 2021-06-14 Gmax Biopharm Llc Preparation of stabilized solution of a fusion protein of a pharmaceutical GLP-1R antibody
WO2023066988A1 (en) 2021-10-19 2023-04-27 Sandoz Ag Glass container with low aluminum content and gas overlay to prevent oxidation of sensitive therapeutic agents

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR871067B (en) * 1986-07-18 1987-11-19 Chugai Pharmaceutical Co Ltd Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
JP2577742B2 (en) 1986-07-18 1997-02-05 中外製薬株式会社 Stable granulocyte colony-stimulating factor containing preparation
JP2577744B2 (en) * 1986-07-18 1997-02-05 中外製薬株式会社 Stable granulocyte colony-stimulating factor containing preparation
JPH02116515A (en) 1988-10-26 1990-05-01 Matsushita Electric Works Ltd Manufacture of inorganic building material
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5272135A (en) * 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
DE4126984A1 (en) 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh PROCESS FOR THE MANUFACTURE OF HUMAN PROTEIN-CONTAINING, SUITABLE MEDICAMENTS FOR INFUSION OR INJECTION USE
DE4242919A1 (en) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Process for the preparation of storage-stable aqueous pharmaceutical preparations of G-CSF
DE4242863A1 (en) 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stable lyophilized pharmaceutical preparations of G-CSF
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
NZ260909A (en) * 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
US5607400A (en) * 1995-05-19 1997-03-04 Becton, Dickinson And Company Pre-fillable syringe and stopper assembly therefor
US6776983B1 (en) * 1998-03-06 2004-08-17 Chugai Seiyaku Kabushiki Kaisha Protein free formulations
JP2000247903A (en) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd Long-term stabilized pharmaceutical preparation
US6646110B2 (en) * 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates

Also Published As

Publication number Publication date
AU2006235962A1 (en) 2006-11-30
HK1057168A1 (en) 2004-03-19
EP1930024A3 (en) 2008-08-06
AU2001282607B2 (en) 2006-08-17
NZ524482A (en) 2005-11-25
WO2002017957A1 (en) 2002-03-07
CN1449292A (en) 2003-10-15
CN1204921C (en) 2005-06-08
EP1329224A4 (en) 2004-04-14
US20040037803A1 (en) 2004-02-26
EP1930024A2 (en) 2008-06-11
CA2420850A1 (en) 2003-02-28
KR20030027077A (en) 2003-04-03
EP1329224A1 (en) 2003-07-23
US7998929B2 (en) 2011-08-16

Similar Documents

Publication Publication Date Title
EP1260230A4 (en) Preparations stabilized over long time
EP1329217A4 (en) Solid preparations
PT1314437E (en) Stabilized antibody-containing preparations
GB0001704D0 (en) Protein
CZ20011229A3 (en) Ophthalmological preparations
AU8260701A (en) Solution preparations stabilized over long time
AU2001282607A1 (en) Solution preparations stabilized over long time
AP2003002783A0 (en) Medicament containing activted antihtrombin iii
GB0011185D0 (en) Protein
AU8252101A (en) Oct preparations
GB0124032D0 (en) Protein
AU2001282521A1 (en) OCT preparations
HK1053062A1 (en) Pernasally absorbable insulin preparations
GB0009181D0 (en) Protein
EP1179592A4 (en) Proteins nectin-3
IL150774A0 (en) Apoptin-associating protein
EP1323734A4 (en) Irap-binding protein
GB0011269D0 (en) Protein over expression
GB0008549D0 (en) Protein
GB0119929D0 (en) Protein
GB0027308D0 (en) Drug-activated proteins
GB0007039D0 (en) C fit
GB0001782D0 (en) Cellular preparations
GB0015307D0 (en) Protein
GB0014825D0 (en) Protein